

Supplementary Online Content

Hernandez-Alejandro R, Ruffolo LI, Sasaki K, et al. Recipient and donor outcomes after living donor liver transplant for unresectable colorectal liver metastases. *JAMA Surg*. Published online March 30, 2022. doi:10.1001/jamasurg.2022.0300

eTable. Inclusion and Exclusion Criteria of Participating LDLT Centers

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Inclusion and Exclusion Criteria of Participating LDLT Centers

University of Rochester	Cleveland Clinic	University Health Network
<ul style="list-style-type: none">• Primary Tumor Removed• Response to Chemotherapy ≥ 12 months• No Evidence of Extrahepatic Disease• CEA < 80 ng/dL• Patient ECOG 0 or 1 and age ≤ 65• Absence of synergistic tumor mutations (KRAS & TP53)• Oslo Score ≤ 2	<ul style="list-style-type: none">• > 12 Months From Primary Tumor Removal• Response to Chemotherapy 6-12 months• No Evidence of Extrahepatic Disease• CEA < 100 ng/dL• Patient ECOG 0 or 1 and age ≤ 65• Absence of tumor mutation (BRAF)	<ul style="list-style-type: none">• Response to Chemotherapy at least 6 months• Primary CRC resected > 6 months• No Evidence of Extrahepatic Disease• CEA stable or decreasing at all points prior to liver transplant• Patient ECOG 0 or 1 and age 18-68• Absence of tumor mutation (BRAF)